IndegeneNSE:INDGN -0.23%49 EBITDA Margin % is 15.36% as of Mar. 2026, which is 27% below its 10-year median of 21.07. GuruFocus rates NSE:INDGN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Indegene ranks better than 71.73% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Indegene's EBITDA for the
three
months ended in Mar. 2026 was ₹1,541 Mil. Indegene's Revenue for the
three
months ended in Mar. 2026 was ₹10,034 Mil. Therefore, Indegene's EBITDA margin for the quarter that ended in Mar. 2026 was 15.36%.
Indegene (NSE:INDGN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Indegene EBITDA Margin % Related Terms
Indegene EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Indegene's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDGN vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Indegene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indegene EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indegene's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Indegene's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indegene (NSE:INDGN) has a EBITDA Margin % of 15.36% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indegene and its competitors. This is 27% below median its historical median of 21.07. Over the past decade, Indegene's EBITDA Margin % has ranged from 15.90 to 31.58. According to the industry distribution chart, Indegene ranks #188 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 28.3%.
Is Indegene's EBITDA Margin % too high?
Indegene's current EBITDA Margin % of 15.36% is 27% below median its 10-year median of 21.07. Over the past 10 years, this metric has ranged from a low of 15.90 to a high of 31.58. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Indegene's value of 15.36% is 50% above this industry median. Based on the distribution chart, Indegene ranks #188 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Indegene has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Indegene's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Indegene ranks #188 out of 665 companies for EBITDA Margin %. This puts Indegene in the upper half of its industry. The industry median EBITDA Margin % is 10.24. Indegene's value of 15.36% is 50% above this benchmark. Historically, Indegene's own EBITDA Margin % has ranged from 15.90 to 31.58 over the past decade. While the company's 10-year median is 21.07 vs. the industry median of 10.24, Indegene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indegene's current EBITDA Margin % of 15.36% is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indegene and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indegene's current EBITDA Margin % is 15.36%, which is 27% below median its own 10-year median of 21.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indegene stock overvalued right now?
Indegene (NSE:INDGN) has a current EBITDA Margin % of 15.36%. The current EBITDA Margin % is 15.36%, which is 27% below median its 10-year median of 21.07 and 50% above the Healthcare Providers & Services industry median of 10.24. Indegene's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indegene (NSE:INDGN), the current EBITDA Margin % is 15.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
49GF Score
Get the complete analysis for NSE:INDGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDGN has been successfully added to your 
